Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Remacemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remacemide SCHEMBL20769836 | 0.98 | CYP1A2 (1.00) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| Remacemide SCHEMBL151148 | 0.98 | CYP1A2 (1.00) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| Remacemide SCHEMBL7266094 | 0.92 | CYP3A4 (0.86) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| Remacemide SCHEMBL31270066 | 0.92 | CYP3A4 (0.86) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| Remacemide SCHEMBL7266326 | 0.92 | CYP3A4 (0.86) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| Hydrochloric Acid SCHEMBL9513957 | 0.90 | MAPK1 (0.82) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| SCHEMBL5300822 | 0.90 | CYP3A4 (0.84) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| SCHEMBL9054250 | 0.90 | CYP3A4 (0.84) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| SCHEMBL5300046 | 0.90 | CYP3A4 (0.84) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 | |
| Hydrochloric Acid SCHEMBL9172429 | 0.90 | MAPK1 (0.81) | MAPK1CYP1A2CYP3A4RECQLCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | claimed |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2011008298-A2 | NOVEL AXOMADOL DOSAGE FORMS | NECTID, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| WO-2008010794-A1 | PHARMACEUTICAL PREPARATIONS OF CRYSTALLINE LAZABEMIDE | RENAISSANCE MEDICINE, LLC (US) | 2008-01-24 | — | — | WO | claimed |
| EP-1309301-A4 | MEDICATED WRAP | HYSON MORTON I (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1309301-A1 | MEDICATED WRAP | Hyson, Morton I. (US) | 2003-05-14 | — | — | EP | claimed |
| EP-1175209-A2 | USE OF ANTIEPILEPTICS FOR TREATING RESPIRATORY DISORDERS, IN PARTICULAR ASTHMATIC DISORDERS | Lomia, Merab (GE) | 2002-01-30 | — | — | EP | claimed |
| WO-2001080797-A1 | MEDICATED WRAP | HYSON MORTON I (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0946497-B1 | PROCESS FOR THE PREPARATION OF NMDA ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-10-17 | — | — | EP | claimed |
| WO-2000066096-A2 | USE OF ANTIEPILEPTICS FOR TREATING RESPIRATORY DISORDERS, IN PARTICULAR ASTHMATIC DISORDERS | LOMIA MERAB (GE) | 2000-11-09 | — | — | WO | claimed |
| US-6063962-A | Process for the preparation of NMDA antagonists | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-05-16 | — | — | US | claimed |
| EP-0946497-A1 | PROCESS FOR THE PREPARATION OF NMDA ANTAGONISTS | Astra Pharmaceuticals Limited (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027052-A1 | PROCESS FOR THE PREPARATION OF NMDA ANTAGONISTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-06-25 | — | — | WO | claimed |
| EP-0279937-B1 | 2-AMINOACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1991-10-09 | — | — | EP | claimed |
| EP-0279937-A1 | 2-Aminoacetamide derivatives | FISONS CORPORATION (US) | 1988-08-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | SLC6A2 272/4885MMP8 4705/4885MAPK1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.